ENTA - Enanta gives pipeline update ahead of next week's JPM conference

Clinical-stage biotechnology company Enanta Pharmaceuticals ([[ENTA]] -1.2%) talks up its pipeline products ahead of the annual J.P. Morgan Healthcare Conference scheduled next week.The company aims to progress its all-oral, triple regimen that could be a functional cure for patients living with chronic Hepatitis EDP-721 study into a Phase 1 clinical trial by mid-2021.Enanta also expects to post preliminary information from an initial interim analysis of its Phase 2b NASH study of EDP-305 around mid-year.Enanta’s President and Chief Executive Officer Jay Luly will provide an update across its pipeline programs in virology and non-alcoholic steatohepatitis ((NASH)) at the conference.Enanta had cash balance of $419M at September 30, 2020.

For further details see:

Enanta gives pipeline update ahead of next week's JPM conference